









Markets
/
Stocks
/
nasdaq-mcrb
/

Seres Therapeutics Inc

MCRB

17.450USD

-0.580-3.22%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

152.77MMarket Cap

1.78P/E TTM



Seres Therapeutics Inc

17.450

-0.580-3.22%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite an average stock market performance, the company shows strong fundamentals and technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

69 / 506

Overall Ranking

163 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

40.600

Target Price

+125.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Seres Therapeutics, Inc. is a clinical-stage company focused on improving patient outcomes in medically vulnerable populations through novel live biotherapeutics. The Company is engaged in developing SER-155, which has demonstrated a significant reduction in bloodstream infections and related complications (as compared to placebo) in a clinical study in patients undergoing allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT). The Company is also advancing additional cultivated oral live biotherapeutics for medically vulnerable populations, including those with chronic liver disease, cancer neutropenia, and solid organ transplants. The Company's clinical and nonclinical data across its programs support the development of live biotherapeutics to target the prevention and treatment of a broad swath of infections, and in inflammatory and immune diseases.

Turnaround to Profit

The company's performance has turned profitable, with the latest annual net income of USD 136.00K.%!(EXTRA int=2)

Overvalued

The company’s latest PE is 1.54, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 4.24M shares, decreasing 19.16% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 292.10K shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 8.20, which is higher than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is robust, and its operating efficiency is high.

Score

Industry at a Glance

Previous score

8.20

Change



Financials

10.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.24

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

6.73

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.03

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 7.82, which is higher than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is 1.60, which is -131.84% below the recent high of -0.51 and 223.28% above the recent low of -1.97.

Score

Industry at a Glance

Previous score

7.82

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 69/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Seres Therapeutics Inc is 17.00, with a high of 122.40 and a low of 6.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

40.600

Target Price

+125.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Seres Therapeutics Inc

MCRB

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 6.49, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 23.72 and the support level at 13.28, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.49

Change

-0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(4)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.693

Neutral

RSI(14)

50.158

Neutral

STOCH(KDJ)(9,3,3)

32.610

Neutral

ATR(14)

2.275

High Vlolatility

CCI(14)

-31.619

Neutral

Williams %R

69.076

Sell

TRIX(12,20)

0.241

Sell

StochRSI(14)

73.435

Sell

Moving Average

Sell(2)

Neutral(0)

Buy(4)

Indicators

Value

Direction

MA5

17.236

Buy

MA10

17.875

Sell

MA20

18.488

Sell

MA50

16.226

Buy

MA100

12.361

Buy

MA200

13.740

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 48.50%, representing a quarter-over-quarter increase of 0.44%. The largest institutional shareholder is The Vanguard, holding a total of 292.10K shares, representing 3.34% of shares outstanding, with 1.73% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Flagship Ventures

1.16M

Nestle SA

1.09M

+186.83%

The Vanguard Group, Inc.

Star Investors

304.60K

+3.71%

Fidelity Management & Research Company LLC

1.09M

+0.20%

BlackRock Institutional Trust Company, N.A.

84.10K

Geode Capital Management, L.L.C.

80.94K

+7.17%

Bank Vontobel AG

54.30K

+15.74%

Charles Schwab Investment Management, Inc.

41.70K

-3.66%

State Street Global Advisors (US)

25.04K

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.12, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 0.19. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.